Mitotix, Inc.

Gpc Biotech, Inc.

Peggy L Beer-Romero

Mark Rolfe

Giulio Draetta

Susan J Glass

Peter J Strack

The present invention relates to the discovery in eukaryotic cells, particularly human cells, of novel protein-protein interactions between certain cellular proteins, referred to herein as 'E6AP-binding proteins' or 'E6AP-BPs', and the cellular protein E6AP, the latter of which is a component of a ubiquitin-ligase (E3) enzyme. The association of E6AP and the subject E6AP-binding proteins implicates the E6AP-binding proteins in a number of basic cellular functions, such as regulation of gene expression, regulation of the cell-cycle, modification of cell surface receptors, biogenesis of ribosomes, and DNA repair. One of the E6AP-binding proteins shares certain homology with the papillomavirus E6 protein, which also binds E6AP.

E6AP-binding proteins

The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of I.kappa.B and other I.kappa.B-related polypeptides.

Regulation of I Kappa B (I.kappa.B) degradation and methods and reagents

The present invention relates to the discovery that antisense nucleic acids complimentary to an E6AP gene can be used to regulate cellular p53 levels. In general the invention features E6AP antisense constructs which, by inhibiting E6AP activity, can modulate cellular p53 levels in both p53+ transformed cells and in normal cells. The invention also provides methods for treating papillomavirus (PV) induced condition, methods for regulating cellular p53 levels and methods for regulating cellular proliferation.

Growing community of inventors

Arlington, MA, United States of America

Peggy L Beer-Romero